NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

腫瘤性骨質軟化病(TIO) - 市場洞察,流行病學,市場預測 2028年

Tumor Induced Osteomalacia (TIO) - Market Insights, Epidemiology and Market Forecast 2028

出版商 DelveInsight Business Research LLP 商品編碼 773913
出版日期 按訂單生產 內容資訊 英文 100 Pages
商品交期: 2-10個工作天內
價格
腫瘤性骨質軟化病(TIO) - 市場洞察,流行病學,市場預測 2028年 Tumor Induced Osteomalacia (TIO) - Market Insights, Epidemiology and Market Forecast 2028
出版日期: 按訂單生產內容資訊: 英文 100 Pages
簡介

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的腫瘤性骨質軟化病(TIO)市場調查,總括性彙整疾病概要和現行的治療方法,新藥的簡介,整體及各國的市場趨勢,流行病學預測,市場規模,患病數·罹患數的變化與預測,未滿足需求,市場成長要素及障礙等資訊。

目錄

第1章 簡介

第2章 腫瘤性骨質軟化病(TIO)市場概要

  • 市場佔有率分析(實際成果值)
  • 市場佔有率分析(預測值)

第3章 疾病背景和概要:腫瘤性骨質軟化病(TIO)

  • 簡介
  • 症狀
  • 病因
  • 危險因素
  • 病理學
  • 診斷
  • 治療

第4章 流行病學和患者人口

  • 主要調查結果
  • 腫瘤性骨質軟化病(TIO)的患病數·罹患數
  • 腫瘤性骨質軟化病(TIO)的患病數 - 各國

第5章 腫瘤性骨質軟化病(TIO)的流行病學:各國

  • 美國
    • 假設和理論的根據
    • 腫瘤性骨質軟化病(TIO)的患病數·罹患數
    • 腫瘤性骨質軟化病(TIO)的病例數:疾病類型
    • 腫瘤性骨質軟化病(TIO)的病例數:性別
    • 腫瘤性骨質軟化病(TIO)的診斷數
    • 腫瘤性骨質軟化病(TIO)的可治療病例數
  • 歐盟5國
    • 假設和理論的根據
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第6章 現行治療

  • 治療流程
  • 治療指南

第7章 未滿足需求

第8章 已上市治療藥

  • 醫藥品 A
    • 醫藥品概要
    • 作用機制
    • 法規的里程碑
    • 優點與缺點
    • 產品簡介
  • 醫藥品 B

第9章 開發平台治療藥

第10章 主要交叉比較

第11章 新藥

  • 醫藥品 C
    • 醫藥品概要
    • 臨床試驗詳細內容
    • 安全性和有效性的簡介
    • 優點與缺點
    • 開發平台開發趨勢
    • 產品簡介
  • 醫藥品 D

第12章 市場分析腫瘤性骨質軟化病(TIO):主要7個國家

  • 市場規模
  • 已上市治療藥的市場佔有率
  • 腫瘤性骨質軟化病(TIO)治療藥的銷售額:各產品

第13章 腫瘤性骨質軟化病(TIO):各國市場分析

  • 美國
    • 市場規模
    • 已上市治療藥的市場佔有率
    • 腫瘤性骨質軟化病(TIO)治療藥的銷售額:各產品
    • 新藥及其對市場的影響
  • 歐盟5國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第14章 市場成長要素

第15章 市場障礙

第16章 附錄

第17章 調查手法

  • 出處

第18章 DelveInsight的服務內容

第19章 免責聲明

第20章 關於DelveInsight

目錄
Product Code: DIMI0487

DelveInsight's "Tumor Induced Osteomalacia(TIO) - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Tumor Induced Osteomalacia(TIO) epidemiology and market outlook for the 7MM.Tumor-induced osteomalacia (TIO) - also known as oncogenic osteomalacia - is a rare paraneoplastic syndrome characterized by phosphaturic osteomalacia linked to a phosphaturic mesenchymal tumor (PMT) which induces renal phosphate wasting by secreting phosphatonin-like factors that inhibits phosphate renal reuptake. TIO is generally caused by the development of a tumor that releases fibroblast growth factor 23 (FGF23). FGF23 inhibits the ability of the kidneys to absorb phosphate, which is important for keeping bones strong and healthy. Therefore, this disease is characterized by a softening and weakening of the bones (osteomalacia). The disease also results in multiple biochemical abnormalities including high levels of phosphate in the urine (hyperphosphaturia) and low levels of phosphate in the blood (hypophosphatemia). The majority of tumors that cause oncogenic osteomalacia are benign, small and slow-growing. These tumors most commonly occur in the skin, muscles, or bones of the extremities or in the paranasal sinuses around the head.

The most frequent clinical symptoms associated Tumor-induced osteomalacia are muscular cramping, generalized weakness, chronic fatigue, bone pain, severe bone demineralization with increased risk of fractures.

Markets Covered:

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Understanding and Treatment Algorithm:

The market report provides the overview of the Tumor Induced Osteomalacia(TIO) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Epidemiology:

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Tumor Induced Osteomalacia(TIO) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Product Profiles & Analysis:

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Market Outlook:

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Tumor Induced Osteomalacia(TIO) market.

Market Share by Therapies:

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Report Insights:

  • Patient Population in Tumor Induced Osteomalacia(TIO)
  • Therapeutic Approaches in Tumor Induced Osteomalacia(TIO)
  • Tumor Induced Osteomalacia(TIO) Pipeline Analysis
  • Tumor Induced Osteomalacia(TIO) Market Size and Trends
  • Tumor Induced Osteomalacia(TIO) Market Opportunities
  • Impact of upcoming Therapies in Tumor Induced Osteomalacia(TIO)

Report Key Strengths:

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Report Assessment:

  • Current Treatment Practices in Tumor Induced Osteomalacia(TIO)
  • Unmet Needs in Tumor Induced Osteomalacia(TIO)
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits:

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Tumor Induced Osteomalacia(TIO) market
  • Organize sales and marketing efforts by identifying the best opportunities for Tumor Induced Osteomalacia(TIO) market
  • To understand the future market competition in the Tumor Induced Osteomalacia(TIO) market.

Table of Contents

1. Report Introduction

2. Tumor Induced Osteomalacia(TIO) Market Overview at a Glance

  • 2.1. Market Share Distribution of Tumor Induced Osteomalacia(TIO) in 2016
  • 2.2. Market Share Distribution of Tumor Induced Osteomalacia(TIO) in 2028

3. Disease Background and Overview: Tumor Induced Osteomalacia(TIO)

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Tumor Induced Osteomalacia(TIO) in 7MM
  • 4.3. Total Prevalent Patient Population of Tumor Induced Osteomalacia(TIO) in 7MM - By Countries

5. Epidemiology of Tumor Induced Osteomalacia(TIO) by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO)
    • 5.1.3. Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) *
    • 5.1.4. Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) *
    • 5.1.5. Diagnosed Cases of the Tumor Induced Osteomalacia(TIO)
    • 5.1.6. Treatable Cases of the Tumor Induced Osteomalacia(TIO)
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO)
    • 5.4.3. Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) *
    • 5.4.4. Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) *
    • 5.4.5. Diagnosed Cases of the Tumor Induced Osteomalacia(TIO)
    • 5.4.6. Treatable Cases of the Tumor Induced Osteomalacia(TIO)
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO)
    • 5.5.3. Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) *
    • 5.5.4. Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) *
    • 5.5.5. Diagnosed Cases of the Tumor Induced Osteomalacia(TIO)
    • 5.5.6. Treatable Cases of the Tumor Induced Osteomalacia(TIO)
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO)
    • 5.6.3. Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) *
    • 5.6.4. Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) *
    • 5.6.5. Diagnosed Cases of the Tumor Induced Osteomalacia(TIO)
    • 5.6.6. Treatable Cases of the Tumor Induced Osteomalacia(TIO)
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO)
    • 5.7.3. Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) *
    • 5.7.4. Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) *
    • 5.7.5. Diagnosed Cases of the Tumor Induced Osteomalacia(TIO)
    • 5.7.6. Treatable Cases of the Tumor Induced Osteomalacia(TIO)
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO)
    • 5.8.3. Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) *
    • 5.8.4. Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) *
    • 5.8.5. Diagnosed Cases of the Tumor Induced Osteomalacia(TIO)
    • 5.8.6. Treatable Cases of the Tumor Induced Osteomalacia(TIO)
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO)
    • 5.9.3. Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) *
    • 5.9.4. Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) *
    • 5.9.5. Diagnosed Cases of the Tumor Induced Osteomalacia(TIO)
    • 5.9.6. Treatable Cases of the Tumor Induced Osteomalacia(TIO)

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Tumor Induced Osteomalacia(TIO)

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Tumor Induced Osteomalacia(TIO)

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Tumor Induced Osteomalacia(TIO) : 7MM Market Analysis

  • 12.1. 7MM Market Size of Tumor Induced Osteomalacia(TIO)
  • 12.2. 7MM Percentage Share of drugs marketed for Tumor Induced Osteomalacia(TIO)
  • 12.3. 7MM Market Sales of Tumor Induced Osteomalacia(TIO) by Products

13. Tumor Induced Osteomalacia(TIO) : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Tumor Induced Osteomalacia(TIO) in United States
    • 13.1.2. Percentage Share of drugs marketed for Tumor Induced Osteomalacia(TIO) in United States
    • 13.1.3. Market Sales of Tumor Induced Osteomalacia(TIO) by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Tumor Induced Osteomalacia(TIO) in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Tumor Induced Osteomalacia(TIO) in Germany
      • 13.2.1.3. Market Sales of Tumor Induced Osteomalacia(TIO) by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Tumor Induced Osteomalacia(TIO) in France
      • 13.2.2.2. Percentage Share of drugs marketed for Tumor Induced Osteomalacia(TIO) in France
      • 13.2.2.3. Market Sales of Tumor Induced Osteomalacia(TIO) by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Tumor Induced Osteomalacia(TIO) in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Tumor Induced Osteomalacia(TIO) in Italy
      • 13.2.3.3. Market Sales of Tumor Induced Osteomalacia(TIO) by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Tumor Induced Osteomalacia(TIO) in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Tumor Induced Osteomalacia(TIO) in Spain
      • 13.2.4.3. Market Sales of Tumor Induced Osteomalacia(TIO) by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Tumor Induced Osteomalacia(TIO) in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Tumor Induced Osteomalacia(TIO) in United Kingdom
      • 13.2.5.3. Market Sales of Tumor Induced Osteomalacia(TIO) by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Tumor Induced Osteomalacia(TIO) in Japan
    • 13.3.2. Percentage Share of drugs marketed for Tumor Induced Osteomalacia(TIO) in Japan
    • 13.3.3. Market Sales of Tumor Induced Osteomalacia(TIO) by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Tumor Induced Osteomalacia(TIO) in United States (2016-2028)
  • Table 7: Treatable Cases of the Tumor Induced Osteomalacia(TIO) in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Tumor Induced Osteomalacia(TIO) in Germany (2016-2028)
  • Table 12: Treatable Cases of the Tumor Induced Osteomalacia(TIO) in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) in France (2016-2028)
  • Table 16: Diagnosed Cases of the Tumor Induced Osteomalacia(TIO) in France (2016-2028)
  • Table 17: Treatable Cases of the Tumor Induced Osteomalacia(TIO) in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Tumor Induced Osteomalacia(TIO) in Italy (2016-2028)
  • Table 22: Treatable Cases of the Tumor Induced Osteomalacia(TIO) in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Tumor Induced Osteomalacia(TIO) in Spain (2016-2028)
  • Table 27: Treatable Cases of the Tumor Induced Osteomalacia(TIO) in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Tumor Induced Osteomalacia(TIO) in UK (2016-2028)
  • Table 32: Treatable Cases of the Tumor Induced Osteomalacia(TIO) in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Tumor Induced Osteomalacia(TIO) in Japan (2016-2028)
  • Table 37: Treatable Cases of the Tumor Induced Osteomalacia(TIO) in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Tumor Induced Osteomalacia(TIO) in USD MM (2016-2028)
  • Table 42:7MM- Market Share Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Tumor Induced Osteomalacia(TIO) in USD MM (2016-2028)
  • Table 45: United States-Market Share Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Tumor Induced Osteomalacia(TIO) in USD MM (2016-2028)
  • Table 48: Germany-Market Share Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Tumor Induced Osteomalacia(TIO) in USD MM (2016-2028)
  • Table 51: France-Market Share Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Tumor Induced Osteomalacia(TIO) in USD MM (2016-2028)
  • Table 54: Italy-Market Share Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Tumor Induced Osteomalacia(TIO) in USD MM (2016-2028)
  • Table 57: Spain-Market Share Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Table 59: UK-Market Size of Tumor Induced Osteomalacia(TIO) in USD MM (2016-2028)
  • Table 60: UK-Market Share Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Table 61: UK-Market Sales of Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Tumor Induced Osteomalacia(TIO) in USD MM (2016-2028)
  • Table 63: Japan-Market Share Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Tumor Induced Osteomalacia(TIO) in United States (2016-2028)
  • Figure 7: Treatable Cases of the Tumor Induced Osteomalacia(TIO) in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Tumor Induced Osteomalacia(TIO) in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Tumor Induced Osteomalacia(TIO) in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Tumor Induced Osteomalacia(TIO) in France (2016-2028)
  • Figure 17: Treatable Cases of the Tumor Induced Osteomalacia(TIO) in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Tumor Induced Osteomalacia(TIO) in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Tumor Induced Osteomalacia(TIO) in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Tumor Induced Osteomalacia(TIO) in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Tumor Induced Osteomalacia(TIO) in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Tumor Induced Osteomalacia(TIO) in UK (2016-2028)
  • Figure 32: Treatable Cases of the Tumor Induced Osteomalacia(TIO) in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Tumor Induced Osteomalacia(TIO) in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Tumor Induced Osteomalacia(TIO) in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Tumor Induced Osteomalacia(TIO) in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Tumor Induced Osteomalacia(TIO) in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Tumor Induced Osteomalacia(TIO) in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Tumor Induced Osteomalacia(TIO) in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Tumor Induced Osteomalacia(TIO) in USD MM (2016-2028)
  • Figure 45: United States-Market Share Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Tumor Induced Osteomalacia(TIO) in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Tumor Induced Osteomalacia(TIO) in USD MM (2016-2028)
  • Figure 51: France-Market Share Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Tumor Induced Osteomalacia(TIO) in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Tumor Induced Osteomalacia(TIO) in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Figure 59: UK-Market Size of Tumor Induced Osteomalacia(TIO) in USD MM (2016-2028)
  • Figure 60: UK-Market Share Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Figure 61: UK-Market Sales of Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Tumor Induced Osteomalacia(TIO) in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Tumor Induced Osteomalacia(TIO) by Therapies in USD MM (2016-2028)